Celcuity, Inc. (NASDAQ:CELC) Receives $102.29 Average Price Target from Analysts

Shares of Celcuity, Inc. (NASDAQ:CELC) have earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $105.25.

CELC has been the topic of several analyst reports. Jefferies Financial Group raised their price target on shares of Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. Wolfe Research assumed coverage on shares of Celcuity in a research note on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price objective on the stock. Needham & Company LLC set a $95.00 target price on shares of Celcuity in a research note on Monday, October 20th. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. Finally, Guggenheim assumed coverage on Celcuity in a report on Monday, September 22nd. They set a “buy” rating on the stock.

Insider Activity at Celcuity

In other news, Director Richard E. Buller sold 3,900 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $96.73, for a total transaction of $377,247.00. Following the transaction, the director directly owned 7,260 shares in the company, valued at $702,259.80. This represents a 34.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 15.77% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Celcuity

Institutional investors and hedge funds have recently bought and sold shares of the stock. US Bancorp DE grew its stake in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the period. Rhumbline Advisers increased its stake in Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after acquiring an additional 503 shares during the last quarter. Ogorek Anthony Joseph NY ADV acquired a new stake in Celcuity during the third quarter worth about $27,000. Intech Investment Management LLC raised its holdings in shares of Celcuity by 5.2% in the 2nd quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock worth $198,000 after purchasing an additional 734 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Stock Performance

NASDAQ CELC opened at $105.25 on Friday. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. Celcuity has a fifty-two week low of $7.57 and a fifty-two week high of $112.64. The business has a fifty day moving average of $80.09 and a 200-day moving average of $49.13. The stock has a market cap of $4.87 billion, a price-to-earnings ratio of -28.68 and a beta of 0.21.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. As a group, analysts predict that Celcuity will post -2.62 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.